Charles Schwab
MIRM icon

Charles Schwab’s Mirum Pharmaceuticals MIRM Stock Holding History

Charles Schwab’s Portfolio MIRM Stock Details MIRM Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.6M Buy
449,429
+22,339
+5% +$2.24M 0.01% 1210
2026
Q1 		$39.5M Buy
427,090
+17,804
+4% +$1.67M 0.01% 1305
2025
Q4 		$32.3M Buy
409,286
+14,797
+4% +$1.06M 0.01% 1446
2025
Q3 		$28.9M Buy
394,489
+11,329
+3% +$720K ﹤0.01% 1494
2025
Q2 		$19.5M Buy
383,160
+55,282
+17% +$2.46M ﹤0.01% 1688
2025
Q1 		$14.8M Sell
327,878
-4,761
-1% -$224K ﹤0.01% 1780
2024
Q4 		$13.8M Buy
332,639
+4,478
+1% +$187K ﹤0.01% 1879
2024
Q3 		$12.8M Buy
328,161
+17,149
+6% +$684K ﹤0.01% 1914
2024
Q2 		$10.6M Buy
311,012
+39,358
+14% +$1.03M ﹤0.01% 2013
2024
Q1 		$6.82M Buy
271,654
+4,973
+2% +$137K ﹤0.01% 2178
2023
Q4 		$7.87M Buy
266,681
+42,110
+19% +$1.27M ﹤0.01% 2117
2023
Q3 		$7.1M Buy
224,571
+152,287
+211% +$4.17M ﹤0.01% 2094
2023
Q2 		$1.87M Buy
72,284
+19,545
+37% +$520K ﹤0.01% 2570
2023
Q1 		$1.27M Buy
52,739
+956
+2% +$21.8K ﹤0.01% 2659
2022
Q4 		$1.01M Buy
51,783
+1,430
+3% +$28.3K ﹤0.01% 2767
2022
Q3 		$1.06M Buy
50,353
+7,842
+18% +$189K ﹤0.01% 2780
2022
Q2 		$828K Buy
42,511
+27,011
+174% +$637K ﹤0.01% 2864
2022
Q1 		$342K Buy
15,500
+804
+5% +$16.4K ﹤0.01% 3183
2021
Q4 		$235K Hold
14,696
– – ﹤0.01% 3335
2021
Q3 		$293K Sell
14,696
-60,722
-81% -$988K ﹤0.01% 3273
2021
Q2 		$1.3M Sell
75,418
-899
-1% -$16.1K ﹤0.01% 2841
2021
Q1 		$1.51M Buy
76,317
+16,764
+28% +$321K ﹤0.01% 2726
2020
Q4 		$1.04M Buy
59,553
+1,066
+2% +$21K ﹤0.01% 2760
2020
Q3 		$1.13M Buy
58,487
+43,154
+281% +$926K ﹤0.01% 2646
2020
Q2 		$299K Buy
15,333
+4,255
+38% +$71.1K ﹤0.01% 3051
2020
Q1 		$156K Buy
+11,078
New +$182K ﹤0.01% 3057

Other funds holding MIRM

FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
William Blair Investment Management
William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Charles Schwab's MIRM Position: Q2 2026 in Review

Charles Schwab increased its Mirum Pharmaceuticals (MIRM) stake by 5.2% in Q2 2026, buying an estimated $2.24M and bringing the position to 449,429 shares worth $52.6M. The position accounts for 0.01% of the portfolio, ranked #1210.

Charles Schwab first reported a position in MIRM in Q1 2020 and has held it in 26 quarters since. 327 funds tracked by Wall St. Rank hold MIRM as of Q2 2026.

  • Charles Schwab held 449,429 shares of Mirum Pharmaceuticals worth $52.6M as of Q2 2026.
  • Charles Schwab bought 22,339 Mirum Pharmaceuticals shares in Q2 2026, an estimated $2.24M.
  • Mirum Pharmaceuticals made up 0.01% of Charles Schwab's portfolio in Q2 2026, its #1210 holding.
  • Charles Schwab first reported a position in Mirum Pharmaceuticals in Q1 2020 and has held it in 26 quarters since.
  • 327 funds tracked by Wall St. Rank held Mirum Pharmaceuticals as of Q2 2026.

Based on Charles Schwab's 13F filing for Q2 2026, filed 14 Aug 2026.